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Abstract
Background: Most cases of cryptococcal meningitis occur in patients with HIV infection: the course and outcome of 
disease in the apparently immunocompetent is much more poorly understood. We describe a cohort of HIV 
uninfected Vietnamese patients with cryptococcal meningitis in whom underlying disease is uncommon, and relate 
presenting features of patients and the characteristics of the infecting species to outcome.
Methods: A prospective descriptive study of HIV negative patients with cryptococcal meningitis based at the Hospital 
for Tropical Diseases, Ho Chi Minh City. All patients had comprehensive clinical assessment at baseline, were cared for 
by a dedicated study team, and were followed up for 2 years. Clinical presentation was compared by infecting isolate 
and outcome.
Results: 57 patients were studied. Cryptococcus neoformans var grubii molecular type VN1 caused 70% of infections; C. 
gattii accounted for the rest. Most patients did not have underlying disease (81%), and the rate of underlying disease 
did not differ by infecting species. 11 patients died while in-patients (19.3%). Independent predictors of death were age 
≥ 60 years and a history of convulsions (odds ratios and 95% confidence intervals 8.7 (1 - 76), and 16.1 (1.6 - 161) 
respectively). Residual visual impairment was common, affecting 25 of 46 survivors (54.3%). Infecting species did not 
influence clinical phenotype or outcome. The minimum inhibitory concentrations of flucytosine and amphotericin B 
were significantly higher for C. neoformans var grubii compared with C. gattii (p < 0.001 and p = 0.01 respectively).
Conclusion: In HIV uninfected individuals in Vietnam, cryptococcal meningitis occurs predominantly in people with 
no clear predisposing factor and is most commonly due to C. neoformans var grubii. The rates of mortality and visual 
loss are high and independent of infecting species. There are detectable differences in susceptibility to commonly 
used antifungal drugs between species, but the clinical significance of this is not clear.
Background
Cryptococcus neoformans is the most important cause of
invasive fungal disease worldwide. In the absence of HIV,
neurological disease occurs most commonly in patients
with some other cause of immunosuppression, such as
malignancy or organ transplantation. Disease in these
patients, and in HIV patients, is most usually due to
infection with either Cryptococcus neoformans var grubii
(C. grubii), or Cryptococcus neoformans var neoformans
(C. neoformans) [1]. In the tropics and subtropics, Cryp-
tococcus gattii (C. gattii )is a recognized cause of menin-
goencephalitis in the immunocompetent, and it is an
emerging cause of disease in humans and animals in Brit-
ish Columbia [2-7].
Cryptococcal meningitis is rare in immunocompetent
patients - treatment guidelines for these patients are
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although data suggest there are significant differences in
clinical presentation and prognosis between the two
groups[8-20]. We carried out a prospective descriptive
study to determine the clinical presentation and outcome
in HIV negative patients presenting to our hospital with
cryptococcal meningitis.
Methods
Study design
Prospective observational descriptive study.
Setting and participants
The study was conducted at the Hospital for Tropical
Diseases, Ho Chi Minh City, the tertiary referral centre
for infectious diseases in tropical southern Vietnam. The
hospital serves a population of 40 million people and the
well defined patterns of inter-hospital referral in Vietnam
mean all patients in the catchment area with cryptococcal
meningitis are likely be referred for treatment. All
patients received initial treatment and follow-up on the
dedicated central nervous systems (CNS) infection ward.
Ethical approval for the study was from the Hospital for
Tropical Diseases, Viet Nam and the Oxford University
Tropical Ethics Committee, UK.
Entry Criteria
The study was open to adult patients (age≥15 years) in
whom HIV infection was excluded through 2 negative
HIV antibody tests. Cryptococcal meningitis was defined
as follows:
Either: Positive cerebrospinal fluid (CSF) India ink
examination or positive CSF cryptococcal antigen test or
positive CSF cryptococcal culture.
Or: a syndrome consistent with meningoencephalitis (1
or more of headache, neck stiffness, confusion, coma,
convulsions, focal neurology) and culture or antigen posi-
tive blood.
Evidence of other central nervous system infection was
an exclusion criterion.
Patients were recruited between November 1998 and
July 2007. Written informed consent was obtained prior
to study entry.
Patient assessment
All patients were assessed daily by the dedicated study
team. CSF was examined using standard methods includ-
ing Gram's, Ziehl-Neelsen and India ink stains, and cul-
ture on blood, Sabouraud's and Lowenstein-Jensen
media. HIV infection was excluded using Rapid Test and
2 HIV antibody tests (Determine HIV1/2, Abbott, Maid-
enhead, UK).
Microbiology
C. neoformans was identified by the demonstration of
budding encapsulated yeasts on India ink stain of cere-
brospinal fluid (CSF). CSF pellets were cultured at 35°C
on chocolate and blood agar, brain-heart infusion broth,
and at 30°C and 35°C on Sabouraud's agar (Oxoid, Bas-
ingstoke, UK). Identification was confirmed through
demonstration of the growth of characteristic colonies on
bird seed agar and API 32C sugar assimilation tests
(BioMerieux SA, Marcy l'Etoile, France). Isolates were
stored at -30°C on Microbank plastic beads (Pro-Lab
Diagnostics, Neston, Cheshire, UK) and later revived for
speciation. C. gattii was identified by biotyping with
Canavanine Glycine Bromothymol Blue agar, and isolates
were further divided into eight molecular groups using
Polymerase Chain Reaction- Restriction Fragment
Length Polymorphism (PCR-RFLP) analysis of the URA5
gene[21]. Controls were provided by Dr Wieland Meyer,
Westmead Millennium Institute for Medical Research,
Sydney, Australia.
Semi-quantitative Cryptococcus antigen testing was
performed using the Murex Cryptococcus Test (Remel,
Lenexa, USA) according to the manufacturer's instruc-
tions. Sensitivity testing was performed using YeastOne
Sensititre plates (Trek Diagnostic Systems, East Grin-
stead, UK) according to the manufacturer's instructions
on the yeast isolated at presentation, prior to treatment.
All plates were examined at 48 and 72 hours after incuba-
tion at 30°C.
Treatment
Patients were treated according to Vietnamese national
guidelines with intravenous amphotericin B 0.7 to 1mg/
kg/day (Cipla, Mumbai, India) with oral flucytosine
100mg/kg/day (Valeant Pharmaceuticals, Versailles,
France) at the physician's discretion, followed by flucon-
azole 400mg/day (Ranbaxy, Gurgaon, India). Treatment
duration was at the discretion of the attending physician,
guided by the clinical response of the patient. Raised
intracranial pressure was managed by repeated lumbar
puncture.
Follow-up
Patients were followed for 2 years after hospital dis-
charge.
Statistical analysis
All data were entered into an electronic spreadsheet
(Excel, Microsoft, Seattle, USA). Statistical analysis was
performed using STATA version 9 (Statacorp, Texas,
USA). For comparison of proportions of categorical or
dichotomized parameters the chi-squared or Fisher's
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Mann-Whitney U-test was used. Forward step-wise
logistic regression was performed to determine signifi-
cant variables independently associated with outcome.
Results
Clinical Findings
Fifty-seven patients were recruited. Forty patients were
transferred from other hospitals, and the median dura-
tion in these hospitals before transfer was 5 days (inter-
quartile range 1 - 12 days). All had clinical syndromes
consistent with cryptococcal meningitis and all under-
went lumbar puncture. All had positive CSF India ink
examination and positive CSF culture. History and exam-
ination findings on presentation are shown in Additional
file 1: table S1. The duration of symptoms was unclear in
one patient, due to a history of chronic headache (3 years)
prior to diagnosis. The most frequent presenting symp-
toms were headache, fever and neck stiffness. Oculomo-
tor nerve palsies and visual disturbance (decreased acuity
or diplopia) were common on admission, affecting 18
(31.6%) and 27 (47%) patients respectively. Papilloedema
was common, present in 22 of 55 patients (40%, data
missing in 2 patients). Eleven patients (19%) had poten-
tially immunosuppressive pre-existing health problems.
Seven had taken more than three months of corticoster-
oid (nephrotic syndrome (2), Evan's syndrome (2),
chronic arthritis (2) and systemic lupus erythematosus
(1)). Two patients had cirrhosis, one had cirrhosis and
renal impairment and one had diabetes.
Clinical investigations results are shown in Additional
file 1: table S1. The baseline CSF opening pressure was
frequently raised, greater than 30cmCSF in 33 of 54
patients (61%). Generally, CSF showed a predominance of
lymphocytes with low blood glucose to CSF ratio. The
CSF lactate was usually raised. CD4 counts were mea-
sured on a single occasion in 20 patients. 9 patients had
CD4 counts of less than 400 cells/uL, of whom 3 were
receiving treatment with corticosteroids, 2 had renal
impairment and one had lupus.
Imaging Results
56 of 57 patients had chest X-rays on admission. 12 were
abnormal - six showed infiltrative shadowing, five were
consistent with old resolved pulmonary TB, and one
showed bilateral pleural effusions. 39 scans were per-
formed on 36 patients (26 CT brain scans (Toshiba XVI-
sion, Toshiba, Japan), 13 Magnetic Resonance (General
Electric, UK, 1.5T), (MR) brain scans. Abnormalities
included ventricular dilatation, infarction, focal abnor-
malities consistent with cryptococcomas and meningeal
enhancement.
Microbiological Findings
All patients had characteristic encapsulated yeasts seen
on cerebrospinal fluid India ink examination, and positive
CSF culture. 52 patients had CSF cryptococcal antigen
testing - all were positive (median titre 1/256, range 1/4
to 1/32768). Ten of 56 patients (18%) had blood cultured
and were fungaemic, and 44 of 53 patients tested had
cryptococcal antigen detectable in blood, giving this sim-
ple test a sensitivity of 83%. 35 isolates were revivable for
PCR-RFLP typing and antifungal sensitivity testing. 10
were C. gattii, and 25 were C. neoformans var grubii. All
the C. neoformans var grubii fell into molecular group
VN1. One C. gattii isolate was molecular group VG2, the
rest were VG1 (figure 1). One of 10 (10%) patients with C.
gattii infection had underlying disease, versus 7 of 25
(28%) patients with C. neoformans var grubii infection (p
= 0.45, Fisher's exact test).
Susceptibility Testing
Antifungal susceptibility results (Table 1) were interpre-
table for 34 of the 35 isolates (1 isolate grew too slowly
despite incubation at a range of temperatures). Break-
points for Cryptococcus neoformans are not defined; we
present the minimum inhibitory concentrations (MIC) of
drug that inhibited 90% (MIC90) and geometric mean
MICs (GMICs) of the isolates according to species (Table
1). The GMICs of flucytosine and amphotericin were sig-
nificantly higher for C. neoformans var grubii isolates
than for C. gattii (8.23 vs 1.85 μg/ml, (95% CI 7.22 - 9.37
and 1.18 - 2.90, p < 0.001)) and 0.714 μg/ml vs 0.451 μg/
ml, (95% CI 0.617 - 0.826 and 0.341 - 0.598 p = 0.01)
respectively. There were no differences in the MICs of
any other azole by species. We could not detect any asso-
ciation between antifungal susceptibility and clinical out-
come.
Outcome
11/57 (19%) patients died during admission, and the
median time to death was 14 days (4 -156 days). Three
patients withdrew from the study (one after 12 and two
after 37 days of treatment). The median duration of treat-
Figure 1 Representative PCR-RFLP profiles of the URA5 gene of 
20 Cryptococcus isolates and 8 control strains A - H. Footnote: A = 
VN1, B = VN2, C = VN3, D = VN4, E = VG1, F = VG2, G = VG3, H = VG4 * 
denotes examples of detected molecular groups.
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Table 1: Features of 35 cryptococcal meningitis cases according to infecting species.
C. neoformans var grubii C. neoformans var gattii
(n = 25) (n = 10)
Variable Value Value Odds ratio P Value
(Range or %) (range or %) (95% CI)
Median Age (range) 31 (15 - 74) 41 (18 - 53) 0.47
Male Sex 10 (40) 5 (50) 1.48 (0.26 - 8.4) 0.71
Underlying Disease 7 (28) 1 (10) 0.29 (0.01 - 2.9) 0.39
Symptoms
Fever 20 (80) 9 (90) 2.2 (0.2 - 117) 0.64
Headache 19 (90) 8 (89) 0.85 (0.04 - 55.8) 1.0
Vomiting 9 (36) 5 (50) 1.75 (0.31 - 10.1) 0.47
Blurred vision 12 (52) 4 (40) 0.62 (0.10 - 3.47) 0.71
Diplopia 4 (20) 2 (20) 1.0 (0.95 - 10.9) 1.0
Convulsions 4 (16) 1 (10) 0.59 (0.01 - 7.2) 0.59
Signs
GCS < 11/15 7 (28) 1 (10) 0.29 (0.01 - 2.9) 0.39
Neck Stiffness 22 (88) 8 (80) 0.56 (0.05 - 7.8) 0.61
Focal Neurological Signs 7 (28) 5 (50) 2.5 (0.4 - 15.0) 0.26
Papilloedema 5 (21) 5 (50) 3.63 (0.6 - 24.3) 0.11
Investigations
Abnormal Chest X-ray 8 (32) 2 (20) 0.54 (0.05 - 3.7) 0.69
Abnormal Brain Imaginga 7 (58) 7(100) - 0.13
Haematocrit 37.8 (25.3 - 51.4) 38.8 (31.1 - 46) 0.65
Blood White Cell Count (×10^9/ml) 11.5(3.3 - 26.6) 13.6 (7.1 - 26.1) 0.37
Platelet count (×10^9/L) 256 (56.9 - 356) 305 (140 - 487)
CSF opening pressure (cmCSF)b 34.2 (2 - > 40) 30.5 (15 - > 40) 0.44
CSF White Cell Count/ml 287 (2 - 1080) 279 (12 - 480) 0.18
CSF Lymphocyte %c 53 (12 - 97) 56 (19 - 93) 0.74
CSF Protein (g/L) 1.28 (0.35 - 2.63) 1.25 (0.4 - 1.94) 0.9
Log2 CSF Cryptococcal antigen titre5 7.4 (3 - 15) 8.6 (2 - 14) 0.5
Lactate (mmol/L) 6.2 (1.6 - 22.5) 4.2 (2 - 8.4) 0.052
Antifungal MICs (mg/L)
Amphotericin GM(95%CI) 0.71 (0.62 - 0.83) 0.45 (0.34 - 0.60) 0.01
MIC90 1.0 0.5
Flucytosine GM(95%CI) 8.23 (7.22 - 9.37) 1.85 (1.18 - 2.90) < 0.001
MIC90 16/0 4.0
Fluconazole GM(95%CI) 6.96 (5.11 - 9.49) 4.54 (2.44 - 8.42) 0.19
MIC90 16.0 16.0
Itraconazole GM(95%CI) 0.11 (0.08 - 0.14) 0.9 (0.05 - 0.14) 0.48
MIC90 0.26 0.26
Voriconazole GM(95%CI) 0.07 (0.05 - 0.09) 0.06 (0.04 - 0.51) 0.85
MIC90 0.13 0.26
Posaconazole GM(95%CI) 0.13 (0.10 - 0.17) 0.10 (0.06 - 0.17) 0.336
MIC90 0.26 0.26
aN = 26, bN = 33, cN = 32, dN = 31
GM = Geometric Mean
MIC90 = minimum inhibitory concentration 90
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Page 5 of 8ment was 131 days (range: 51- 426 days). One (10%) of 10
patients with C. gattii died compared with 6 (24%) of 25
patients with C. neoformans var grubii infection (p =
0.65). Complications at discharge included four patients
with bilateral blindness (no light perception), 4 with uni-
ocular blindness and one with complete visual and hear-
ing loss. All cases of blindness occurred in patients with
opening CSF pressures of ≥ 30cm CSF - 9 of 28 patients
with opening pressure ≥ 30cm CSF developed blindness
compared with none of 17 patients with opening pressure
< 30 cm CSF, p = 0.008). Five of 9 patients with blindness
(56%) had papilloedema at baseline compared with 14
(39%) of 36 patients with no visual loss (odds ratio 1.85,
95% confidence interval 0.33 - 11.09, p = 0.47). There
were no differences in the rates of papilloedema, blind-
ness or opening CSF pressure > 30cmCSF by infecting
species. Fourteen patients had other neurological deficits
including blurred vision and/or cranial nerve palsies.
On univariate analysis the admission findings associ-
ated with death were presence of underlying disease, his-
tory of convulsions, Glasgow Coma Score ≤ 11, age ≥ 60
years, lower platelet count, CSF cryptococcal antigen titre
≥ 1/512 and CSF yeast cell count > 400 cells/ml. Six of 21
(29%) patients with CSF opening pressure < 30cm CSF
died, compared with 7 of 33 (21%) patients with opening
pressures ≥ 30cm CSF (odds ratio 0.68, 95% confidence
interval 0.16 - 2.94, p = 0.745). Two of 9 patients with
CD4 lymphopenia died.
Multivariate analysis was limited by the small number
of deaths. We tested the interaction between easily mea-
sured clinical parameters (age ≥ 60 years, underlying dis-
ease, Glasgow coma score < 11 and convulsions) with
outcome. Only age ≥ 60 years and a history of convulsions
were independently associated with death (Additional file
1: table S1). Length of history had no impact on outcome.
We could detect no differences in clinical phenotype or
outcome according to infecting species.
Two years after diagnosis a further 4 patients had died
(total deaths 15 of 57, 26.3%). 14 patients (24.6%) had
made complete recoveries with no residual deficit. One
died due to multi-drug resistant tuberculosis, compli-
cated by relapse of cryptococcal disease. Three patients
with underlying disease continued on long term flucon-
azole prophylaxis. It was not possible to determine the 2
year outcome in 9 of the 57 patients.
Discussion
Cryptococcal meningitis in HIV uninfected patients in
tropical Viet Nam is most commonly due to Cryptococcus
neoformans var grubii. Most patients (81%) have no con-
comitant immunosuppressive disease, although CD4
lymphopenia was detected in 9 patients, 3 of whom had
no other underlying conditions.
C. neoformans var grubii, the commonest cause of
cryptococcal meningitis since the HIV epidemic, usually
occurs in patients with an underlying immunosuppres-
sive condition and has rarely been reported in the
absence of underlying disease, in southeast Asia or else-
where [2,12,14,22-27]. Classical teaching would suggest
that, in our tropical location, more cases would have been
due to infection with Cryptococcus gattii[28,29]. Against
expectation, in our series C. neoformans var grubii infec-
tion outweighed C. gattii infection 2.5-fold. We could
only revive isolates for speciation from 35 patients, but
since the study has finished we continue to isolate C. neo-
formans var grubii and C. gattii from HIV uninfected
patients in the ratio 3:1. We could not detect differences
in the rate of underlying disease according to infecting
species, although our study lacked power since there
were only 10 cases of C. gattii infection.
All patients in our study had positive CSF India ink
examination and culture - a rate higher than generally
reported in the literature [1]. This may be a reflection of
the large volumes of CSF (5 - 10 mls) routinely taken from
patients with suspected meningitis in our hospital in
order to exclude tuberculous meningitis.
In the tropical Northern Territories of Australia the
incidences of C. gattii and C. neoformans infection are
equal[30]. In Queensland the experience is more like our
own - in a 3 year period C. neoformans infections out-
weighed C. gattii 5 fold, although the total number of
cases is not clear from the report[30]. However, it is not
clear whether these cases were meningoencephalitis or
extra-neural disease, and the varietal form of C. neofor-
mans was not described for the majority of isolates.
All the C. neoformans var grubii strains from our series
were of URA5-RFLP molecular type VN1, as also recently
reported from China [31]. In that series, there was
remarkable genetic homogeneity between the VN1 iso-
lates, perhaps representing a strain in Asia with increased
ability to cause infection in the immunocompetent.
The significance of CD4 lymphopenia in our patients is
uncertain. Only 20 patients had the investigation, and the
test was not performed serially. Thus it is not clear
whether it represents a transient phenomenon as a conse-
quence of infection, or whether it represents a genuine
pre-existing immune deficit, such as idiopathic CD4 lym-
phopenia, known to be associated with an increased risk
of cryptococcosis [32]. HIV infection is unlikely since
each patient received at least 2 HIV antibody tests.
While cryptococcal meningitis remains rare in HIV
uninfected patients, when it occurs the consequences are
severe [33]. The death rate in our patients is 19% at hospi-
tal discharge, and blindness affects 20% of survivors.
Most patients were admitted to provincial or district hos-
pitals before transfer to our centre, and delay in diagnosis
may play a role in the high death rate seen in this disease,
Chau et al. BMC Infectious Diseases 2010, 10:199
http://www.biomedcentral.com/1471-2334/10/199
Page 6 of 8although we did not find length of history to be associ-
ated with death. The independent variables associated
with death were age and convulsions. We did not find the
presence of underlying disease to be independently asso-
ciated with outcome, although analysis was limited by the
low number of deaths. CSF opening pressure at baseline
was highly associated with development of blindness, but
there was no association with papilloedema, which prob-
ably reflects the fact that papilloedema is a late indicator
of raised intracranial pressure. However, it could be a
function of the size of our study. Only 25% of patients
made a complete recovery.
Historically, the disease phenotypes due to infection
with C. neoformans var grubii and C. gattii are considered
to be different. We found no difference in clinical pheno-
type between the 2 infections, and the pattern of disease
seen in our cases mimics that seen in case series of C. gat-
tii infection published from Papua New Guinea[17,27].
Like us, Seaton et al found presence of convulsions to be
a predictor of death in patients with C. gattii meningitis.
In addition, the rate of blindness in our patients is similar
to that reported for C. gattii infection in immunocompe-
tent adults, and higher than in HIV infected patients. The
lack of difference in the clinical phenotypes of disease
according to infecting species and the difference in rates
of visual loss between HIV positive and negative patients
support the hypothesis that host immune status is key in
determining clinical phenotype in cryptococcal dis-
ease[30]. There are retrospective data suggesting that
immune mediating drugs (corticosteroids) may reduce
the risk of blindness in C. gattii infection [34,35]. The
similar clinical phenotype seen in our predominantly C.
neoformans var grubii infected patients suggests that this
may be a worthwhile hypothesis to test in our patients.
There are no established breakpoints for anti-fungal
drugs and C. neoformans, which makes the interpretation
of anti-fungal MICs difficult [36-39]. The geometric
mean MICs of flucytosine and amphotericin B were sta-
tistically significantly higher for C. neoformans var grubii.
This is consistent with the experience in Malaysia, but
differs from reports from Brazil and Taiwan which found
C. gattii to be inherently less susceptible to amphotericin
B and flucytosine [39-41]. Thompson found no difference
in MICs by species, but was comparing strains from mul-
tiple geographic regions[42]. Our data are reassuring,
suggesting that it is safe to extrapolate treatment doses
for our patients with C. gattii from trials in C. neoformans
infection. However, the clinical significance of differences
in MICs of flucytosine and amphotericin B remain
unclear. MIC data were available for only 7 of the isolates
from the 11 patients that died - we could not demonstrate
any correlation between the MIC of any drug and patient
outcome.
Recently, Cryptococcus gattii has been seen to establish
new ecological niches, with subsequent successful
human-mediated dispersal [43]. It is possible that disease
incidence in the immunocompetent will increase [44,45].
There has been little change in the treatment of crypto-
coccal meningitis over the past 10 years. Amphotericin B
remains a key component of treatment, but therapy is
protracted, expensive and difficult to administer. Com-
bined with flucytosine, it has been associated with more
rapid CSF sterilisation in HIV patients, and more recently
slower rates of CSF sterilisation have been shown to be
associated with an increased risk of death [46,47]. The
identification of a reliable surrogate marker of outcome in
cryptococcal meningitis enables anti-fungal therapeutic
trials to be undertaken with smaller numbers of patients,
and it should now be possible to answer clinical questions
in groups where disease is rare, such as HIV uninfected
patients. However, differences in complication rates, such
as blindness, between HIV infected and uninfected
patients may be due to differences in disease pathogene-
sis (perhaps immune mediated) and clinical endpoint tri-
als, although difficult, may still be necessary.
Conclusions
In HIV uninfected individuals in Vietnam, cryptococcal
meningitis occurs predominantly in people with no clear
predisposing factor and is most commonly due to C. neo-
formans var grubii. The pattern of disease is similar to
that described in patients with C. gattii meningitis, sug-
gesting underlying immune status is key in generating
clinical phenotype. The rates of mortality and visual loss
are high and independent of infecting species.
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